公开(公告)号：CA2670368A1

公开(公告)日：2008-05-29

申请号：CA2670368

申请日：2007-11-21

Applicant: ABBOTT LAB

Inventor： MUELLER REINHOLD ,  GHAYUR TARIQ ,  BARLOW EVE H ,  MUELLER BERNHARD K ,  TEUSCH NICOLE ,  SCHMIDT MARTIN ,  MEYER AXEL ,  MOELLER ACHIM ,  MEZLER MARIO

IPC: A61K39/395

Abstract: The subject invention relates to isolated proteins, particularly monoclon al antibodies, which bind to the Nogo-66 receptor. Specifically, these antib odies have the ability to inhibit the binding of the natural ligand of the N ogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or por tions thereof of the invention are useful for detecting NgR and for inhibiti ng NgR activity, for example in a human suffering from a disorder in which N gR or Nogo-66 activity is detrimental.

公开(公告)号：MX2009005361A

公开(公告)日：2009-06-05

申请号：MX2009005361

申请日：2007-11-21

Applicant: ABBOTT LAB

Inventor： MEZLER MARIO ,  MOELLER ACHIM ,  MUELLER REINHOLD ,  MUELLER BERNHARD K ,  GHAYUR TARIQ ,  BARLOW EVE H ,  SCHMIDT MARTIN ,  MEYER AXEL ,  TEUSCH NICOLE

IPC: A61K39/395

Abstract: El tema de la invención se relaciona con proteínas aisladas particularmente anticuerpos monoclonales, los cuales se unen con el receptor de Nogo-66. Específicamente, los anticuerpos tienen la capacidad de inhibir la unión del ligando natural del receptor de Nogo-66 y neutralizar el receptor de Nogo-66. Estos anticuerpos o porciones de los mismos de la invención son útiles par detectar NgR y para inhibir la actividad de NgR, por ejemplo, en un ser humano que padece un trastorno en el que la actividad de NgR o Nogo-66 es perjudicial.

公开(公告)号：CA2697382A1

公开(公告)日：2009-03-05

申请号：CA2697382

申请日：2008-08-26

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： MACK HELMUT ,  TEUSCH NICOLE ,  MUELLER BERNHARD K ,  HORNBERGER WILFRIED ,  JARVIS MICHAEL F ,  SAUER DARYL ,  SWANN STEVE JR ,  BONAFOUX DOMINIQUE ,  KEDDY RYAN ,  HOBSON ADRIAN DONALD ,  VASUDEVAN ANIL

IPC: C07D213/56 ,  A61K31/44 ,  A61K31/4427 ,  A61P9/00 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

Abstract: The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R1 and R2 are, independently of each other, hydrogen, hydroxy, cyano, C1-C8-alkyl, C1- C8-haloalkyl, C1-C8-alkoxy or C1-C8-haloalkoxy; R3, R4, R5 and R6 are, independently of each other, hydrogen, hydroxy, halogen, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, amino, C1-C8-alkylamino or di-(C1-C8-alkyl)-amino; R7 is hydrogen, C1-C8-alkyl, C1-C8-haloalkyl, aryl or aryl-C1-C8-alkyl; R8 is a group of the formula -X-W, where X is a single bond, C1-C4-alkylene or C1-C4-alkylene-O-, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; R9 is a group of the formula -Y-Z, where Z is hydrogen, halogen, OR11, NR12R13, S(O)m-R14, phenyl which may carry 1, 2, 3 or 4 substituents R15 or a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched C1C4-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond.